SouthState Corp’s Denali Therapeutics DNLI Stock Holding History

SouthState Corp’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30	Closed	-$408	–	1653
2025 Q1	$408	Buy	+30	New	+$575	﹤0.01%	1572

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SouthState Corp's DNLI Position: Q2 2025 in Review

SouthState Corp sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 30 shares — an estimated $408 sold.

SouthState Corp first reported a position in DNLI in Q1 2025 and held it in 1 quarter. The position peaked at $408 in Q1 2025. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

SouthState Corp reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
SouthState Corp sold 30 Denali Therapeutics shares in Q2 2025, an estimated $408.
SouthState Corp first reported a position in Denali Therapeutics in Q1 2025 and held it in 1 quarter.
SouthState Corp's Denali Therapeutics position peaked at $408 in Q1 2025.
230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on SouthState Corp's 13F filing for Q2 2025, filed 6 Aug 2025.